Главная › Множественная миелома › Теннесси › Nashville
Клинические исследования Множественная миелома в городе Nashville, TN
32 исследований по теме Множественная миелома ищут участников в центрах в городе Nashville и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Набор участниковФаза 3
- Research Site, Nashville
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 3
- Tennessee Oncology, PLLC, Nashville
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Набор участниковФаза 1
- Research Site, Nashville
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 3
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Набор участниковФаза 3
- Henry-Joyce Cancer Clinic, Nashville
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Набор участниковФаза 4
- Sarah Cannon Research Institute, Nashville
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 1/2
- Sarah Cannon Research Institute, Nashville
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Набор участниковФаза 2/3
- SCRI Oncology Partners /ID# 278353, Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Набор участниковФаза 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 2
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Набор участниковФаза 2
- SCRI Oncology Partners, Nashville
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 1
- Tennessee Oncology, Nashville
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 1/2
- Research Site, Nashville
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Набор участниковФаза 2
- GSK Investigational Site, Nashville
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Набор участниковФаза 3
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- и еще 2
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Набор участниковФаза 1/2
- GSK Investigational Site, Nashville
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Набор участниковФаза 2
- Vanderbilt University Medical Center, Nashville
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Набор участниковФаза 1/2
- SCRI Oncology Partners, Nashville
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Набор участниковФаза 1
- Tennessee Oncology, Nashville
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Набор участниковФаза 1/2
- Research Site, Nashville
- Research Site, Nashville
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Набор участниковФаза 3
- Research Site, Nashville
- Research Site, Nashville
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Набор участниковФаза 2
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Набор участниковФаза 1
- Tennessee Oncology, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 1
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Набор участниковФаза 3
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Набор участниковФаза 2
- SCRI Oncology Partners, Nashville
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Набор участниковФаза 2
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набор участниковФаза 1/2
- TriStar Centennial Medical Center, Nashville
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Набор участниковФаза 1
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Набор участниковНаблюдательное исследованиеПриглашаются здоровые добровольцы
- Vanderbilt-Ingram Cancer Center, Nashville
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Набор участниковФаза 1
- Tennessee Oncology, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Набор участниковФаза 1/2
- SCRI Oncology Partners, Nashville
Исследования Множественная миелома в других городах
- New York City, NY60 исследований
- Boston, MA42 исследований
- Atlanta, GA41 исследование
- Houston, TX38 исследований
- Durham, NC37 исследований
- Denver, CO27 исследований
- Rochester, MN24 исследований
- St. Louis, MO24 исследований
- Columbus, OH24 исследований
- Baldwin Park, CA23 исследований
- Chicago, IL22 исследований
- Seattle, WA22 исследований
Другие исследования в городе Nashville
- Немелкоклеточный рак легкого97 исследований
- Рак молочной железы80 исследований
- Метастатический рак70 исследований
- Колоректальный рак69 исследований
- Рак (все виды)65 исследований
- Рак яичников49 исследований
- Рак простаты42 исследований
- Рак легких40 исследований
- Плоскоклеточный рак головы и шеи39 исследований
- Рак поджелудочной железы39 исследований
- Рак эндометрия38 исследований
- Меланома33 исследований
Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.